한국인 녹내장 환자에서 브린졸라미드 1.0%/브리모니딘 0.2% 복합제제의 알레르기 임상양상
Clinical Characteristics of Allergy to a Brinzolamide 1.0%/Brimonidine 0.2% Fixed Combination in Korean Glaucoma Patients
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
목적: 한국 녹내장 환자에서 브린졸라미드 1.0%/브리모니딘 0.2% 고정복합제제(brinzolamide 1.0%/brimonidine 0.2% fixed combination, BBFC)의 알레르기 임상양상을 알아보고자 하였다. 대상과 방법: 녹내장으로 진단 받고 BBFC를 사용 중인 환자 117명을 대상으로 후향적 의무기록을 분석하였다. 성별, 나이, 녹내장 형태, 점안약 사용 후 경과 관찰 기간, 병용 약제 수, 알레르기 발생 시기 및 임상특징을 조사하였다. 결과: BBFC 치료 후 알레르기 발생률은 12.8%로 평균 8.58개월(범위: 0.93-25.80개월)에 발생하였으며 알레르기의 절반은 초기 5개월 내에 발생하였다. BBFC에 의한 알레르기는 여포결막염 형태가 53.4%로 가장 많았고, 유두결막염, 눈꺼풀결막염 순이었다. 알레르기를 제외한 전신 부작용과 눈 불편감은 0.09%로 주로 비알레르기군에서 관찰되었다. 결론: 한국 녹내장 환자에서 BBFC 관련 알레르기 임상양상의 파악은 환자 교육 및 점안 순응도 향상에 도움을 줄 것으로 기대한다.
Abstract
Purpose: We describe the clinical aspects of allergy to a brinzolamide 1.0%/brimonidine 0.2% fixed combination (BBFC) in Korean patients with glaucoma. Methods: The medical records of 117 glaucoma patients treated with BBFC were retrospectively analyzed in terms of sex, age, glaucoma type, follow-up period after prescription of eyedrops, number of eyedrop preparations used, allergy onset, and clinical characteristics. Results: The incidence of ocular allergy during BBFC use was 12.8%. Allergy developed after an average of 8.58 months (range, 0.93-25.80 months); half of all allergies were evident within the first 5 months. The most common type of allergy was follicular conjunctivitis (53.4%), followed by papillary conjunctivitis and blepharoconjunctivitis. Systemic side-effects and eye discomfort (0.09%) were largely confined to non-allergic patients. Conclusions: An understanding of the clinical pattern of BBFC allergy in Korean glaucoma patients could facilitate treatment compliance and patients’ education.
참고문헌 (30)
- Collaborative Normal-Tension Glaucoma Study Group, "The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma", Am J Ophthalmol, 126, pp.498~505 (1998)
- Kass MA, "The Ocular Hypertension Treatment Study : a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma", Arch Ophthalmol, 120, pp.701~713 (2002)
- Friedman DS, "An evidence-based assessment of risk factors for the progression of ocular hypertension and glaucoma", Am J Ophthalmol, 138(3 Suppl), pp.S19~S31 (2004)
- Kim CY, "A path analysis of effects of patients'underlying conditions, treatment satisfaction, and adherence on quality of life among Korea glaucoma patients", J Glaucoma, 28, pp.785~789 (2019)
- Sung KR, "Vision-related quality of life in Korean glaucoma patients", J Glaucoma, 26, pp.159~165 (2017)
- Zhang X, "Ocular surface disease and glaucoma medications : a clinical approach", Eye Contact Lens, 45, pp.11~18 (2019)
- Goldenberg MM, "Pharmaceutical approval update", P T, 38, pp.323~324 (2013)
- Schuman JS, "A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension : a controlled, randomized, multicenter clinical trial", Arch Ophthalmol, 115, pp.847~852 (1997)
- Katz LJ, "Brimonidine tartrate 0.2% twice daily vs timolol 0.5%twice-daily: 1-year results in glaucoma patients. Brimonidine Study Group", Am J Ophthalmol, 127, pp.20~26 (1999)
- Melanmed A, "Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol : year-three results", Clin Ther, 22, pp.103~111 (2000)
- Bondeau P, "Allergic reactions to brimonidine in patients treated for glaucoma", Can J Ophthalmol, 37, pp.21~26 (2002)
- Manni G, "Demographic and clinical factors associated with development of brimonidine tartrate 0.2%-induced ocular allergy", J Glaucoma, 13, pp.163~167 (2004)
- Katz LJ, "Twelve-month evaluation of brimonidine-purite versus brimonidine in patiens with glaucoma or ocular hypertension", J Glaucoma, 11, pp.119~126 (2002)
- Kim CY, "Brimonidine 0.2% versus brimonidine Purite 0.15% in Asian ocular hypertension", J Ocul Pharmacol Ther, 23, pp.481~486 (2007)
- 박은정, "녹내장에서 브리모니딘", 티몰롤 복합제제와 0.15% 브리모니딘 사용 시 알레르기 발생률의 비교, 2018, pp.59(5), 451~458[DOI]
- 박한석, "정상안압녹내장에서 브린졸라미드 1%와 티몰롤 0.5% 혼합제제의 효과", 대한안과학회지, 55(7), pp.1056~1063 (2014), 대한안과학회
- 신현욱, "정상안압녹내장에서 브린졸라미드", 브리모니딘 혼합제제의 효과, 2016, pp.57(10), 1619~1624[DOI]
- 김인태, "한국인 정상안압녹내장에서 브린졸라미드 1%와 브리모니딘 0.2% 혼합제제의 임상 효과", 대한안과학회지, 59(6), pp.561~568 (2018), 대한안과학회
- Aung T, "Twice-daily brinzolamide", brimonidine fixed combination versus brinzolamide or brimonidine in open-angle glaucoma or ocular hypertension, 2014, pp.121, 2348~2355
- Taniguchi T, "The potential systemic effect of topically applied β-blockers in glaucoma therapy", Curr Opin Ophthalmol, 8, pp.55~58 (1997)
- Nguyen QH, "Phase 3 randomized 3-month trial with an ongoing 3-month safety extension of fixedcombination brinzolamide 1%", brimonidine 0.2%, 2013, pp.29, 290~297
- Whitson JT, "Six-month results from a phase III randomized trial of fixed-combination brinzolamide 1%+ brimonidine 0.2% versus brinzolamide or brimonidine monotherapy in glaucoma or ocular hypertension", Clin Ophthalmol, 7, pp.1053~1060 (2013)
- Realini T, "Fixed-combination brinzolamide 1%", brimonidine 0.2% vs monotherapy with brinzolamide or brimonidine in patients with open-angle glaucoma or ocular hypertension: results of a pooled analysis of two phase 3studies, 2013, pp.27, 841~847
- Butler P, "Clinical experience with the long-term use of 1% apraclonidine. Incidence of allergic reactions", Arch Ophthalmol, 113, pp.293~296 (1995)
- Hwang HB, "Histopathologic analysis of conjunctival lymphoproliferative disease after topical brimonidine use", J Ocul Pharmacol Ther, 35, pp.503~511 (2019)
- Duffin RM, "2.5% v 10% phenylephrine in maintaining mydriasis during cataract surgery", Arch Ophthalmol, 101, pp.1903~1906 (1983)
- Patil PM, "Unequal accumulation of adrenergic drugs by pigmented and nonpigmented iris", Am J Ophthalmol, 78, pp.470~477 (1974)
- Acheampong AA, "Comparative ocular pharmacokinetics of brimonidine after a single dose application to the eyes of albino and pigmented rabbits", Drug Metab Dispos, 23, pp.708~712 (1995)
- Alvarado JA, "Reduced ocular allergy with fixed-combination 0.2%brimonidine-0.5% timolol", Arch Ophthalmol, 125, pp.717~718 (2007)
- 한종욱, "전신 알레르기 질환과 브리모니딘 점안으로 인한 알레르기결막염의 관계", 대한안과학회지, 60(3), pp.233~238 (2019), 대한안과학회